Challenges in reducing dengue burden; Diagnostics, control measures and vaccines

Expert Review of Vaccines

Volumn 12, Issue 9, 2013, Pages 995-1010

  Lam, Sai K ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

burden; chimeric; dengue; DNA; live attenuated; non replicating; subunit; tetravalent; vaccine introduction; vector control

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

ABDOMINAL PAIN; ANOREXIA; ARTHRALGIA; ASCITES; BLEEDING; BRAZIL; CAPILLARY LEAK SYNDROME; COLOMBIA; COSTA RICA; DENGUE; DETERIORATION; DISSEMINATED INTRAVASCULAR CLOTTING; ENCEPHALITIS; FEVER; FLUSHING; HEADACHE; HEMATOCRIT; HEPATITIS; HEPATOMEGALY; HONDURAS; HUMAN; INCIDENCE; LETHARGY; LEUKOPENIA; METABOLIC ACIDOSIS; MEXICO; MUCOSAL BLEEDING; MYALGIA; MYOCARDITIS; NAUSEA AND VOMITING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; SORE THROAT; THROMBOCYTE COUNT; TOURNIQUET; VENEZUELA; VOMITING;

CLINICAL TRIALS AS TOPIC; DENGUE; DENGUE VACCINES; DRUG DISCOVERY; HUMANS; MOSQUITO CONTROL;

EID: 84885666078     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.824712     Document Type: Review

References (142)

1. Guzman A, Isturiz RE. Update on the global spread of dengue. Int. J. Antimicrob. Agents 36(Suppl. 1), S40-42 (2010).
2. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact of dengue illness in the Americas. Am. J. Trop. Med. Hyg. 84(2), 200-207 (2011).
3. Shepard DS, Suaya JA, Halstead SB et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22(9-10), 1275-1280 (2004). (Pubitemid 38296672)
4. Suaya JA, Shepard DS, Siqueira JB et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am. J. Trop. Med. Hyg. 80(5), 846-855 (2009).
5. Guzman MG, Halstead SB, Artsob H et al. Dengue: a continuing global threat. Nat. Rev. Microbiol. 8(Suppl. 12), S7-16 (2010).
6. Murrell S, Wu SC, Butler M. Review of dengue virus and the development of a vaccine. Biotechnol. Adv. 29(2), 239-247 (2011).
7. Nisalak A, Endy TP, Nimmannitya S et al. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am. J. Trop. Med. Hyg. 68(2), 191-202 (2003). (Pubitemid 38240545)
8. John TJ, Dandona L, Sharma VP, Kakkar M. Continuing challenge of infectious diseases in India. Lancet 377(9761), 252-269 (2011).
9. San Martin JL, Brathwaite O, Zambrano B et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am. J. Trop. Med. Hyg. 82(1), 128-135 (2010).
10. World Health Organization (WHO). Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases, Geneva (2010).
11. Teixeira MG, Costa MC, Coelho G, Barreto ML. Recent shift in age pattern of dengue hemorrhagic fever, Brazil. Emerg. Infect. Dis. 14(10), 1663 (2008).
12. Teixeira MG, Costa Mda C, Barreto F, Barreto ML. Dengue: twenty-five years since reemergence in Brazil. Cad. Saude Publica 25(Suppl. 1), S7-18 (2009).
13. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue virus infection in Africa. Emerg. Infect. Dis. 17(8), 1349-1354 (2011).
14. Caron M, Paupy C, Grard G et al. Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. Clin. Infect. Dis. 55(6), e45-53 (2012).
15. de la C Sierra B, Kouri G, Guzman MG. Race: a risk factor for dengue hemorrhagic fever. Arch. Virol. 152(3), 533-542 (2007). (Pubitemid 46363592)
16. Were F. The dengue situation in Africa. Paediatr. Int. Child Health 32(Suppl. 1), 18-21 (2012).
17. Bhatt S, Gething PW, Brady OJ et al. The global distribution and burden of dengue. Nature 496(7446), 504-507 (2013).
18. Barclay E. Is climate change affecting dengue in the Americas? Lancet 371(9617), 973-974 (2008).
19. Ooi EE, Gubler DJ. Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cad. Saude Publica 25(Suppl. 1), S115-124 (2009).
20. Tapia-Conyer R, Mendez-Galvan JF, Gallardo-Rincon H. The growing burden of dengue in Latin America. J. Clin. Virol. 46(Suppl. 2), S3-6 (2009).
21. Schwartz E, Weld LH, Wilder-Smith A et al. Seasonality, annual trends, and characteristics of dengue among ill returned travelers. 1997-2006. Emerg. Infect. Dis. 14(7), 1081-1088 (2008). (Pubitemid 351920438)
22. Wilder-Smith A, Schwartz E. Dengue in travelers. N. Engl. J. Med. 353(9), 924-932 (2005). (Pubitemid 41247932)
23. Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N. Engl. J. Med. 354(2), 119-130 (2006). (Pubitemid 43076709)
24. Jelinek T. Trends in the epidemiology of dengue fever and their relevance for importation to Europe. Euro. Surveill. 14(25), 1-3 (2009).
25. Centers for Disease Control and Prevention (CDC). Travel-associated dengue surveillance-United States, 2006-2008. MMWR. 59(23), 715-719 (2010).
26. Halstead SB, Suaya JA, Shepard DS. The burden of dengue infection. Lancet 369(9571), 1410-1411 (2007). (Pubitemid 46635764)
27. Torres JR, Castro J. The health and economic impact of dengue in Latin America. Cad. Saude Publica 23(Suppl. 1), S23-31 (2007).
28. Deen JL, Harris E, Wills B et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet 368(9530), 170-173 (2006). (Pubitemid 43994174)
29. Meltzer MI, Rigau-Perez JG, Clark GG, Reiter P, Gubler DJ. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. Am. J. Trop. Med. Hyg. 59(2), 265-271 (1998). (Pubitemid 28418986)
30. Armien B, Suaya JA, Quiroz E et al. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am. J. Trop. Med. Hyg. 79(3), 364-371 (2008).
31. Standish K, Kuan G, Aviles W, Balmaseda A, Harris E. High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. PLoS Negl. Trop. Dis. 4(3), e633 (2010).
32. Shepard DS, Suaya JA. Economic evaluation of dengue prevention. In: Economic Evaluation in Child Health. Ungar, W (Ed). Oxford University Press, Oxford, UK, 225-237 (2009).
33. Pérez-Guerra CL, Halasab YA, Riveraa R et al. Economic cost of dengue public prevention activities in Puerto Rico. Dengue Bulletin 34, 13-23 (2010).
34. Suaya JA, Shepard DS, Chang MS et al. Cost-effectiveness of annual targeted larviciding campaigns in Cambodia against the dengue vector Aedes aegypti. Trop. Med. Int. Health 12(9), 1026-1036 (2007). (Pubitemid 47414941)
35. Beaute J, Vong S. Cost and disease burden of dengue in Cambodia. BMC Public Health 10, 521 (2010).
36. Clark DV, Mammen MP Jr, Nisalak A, Puthimethee V, Endy TP. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am. J. Trop. Med. Hyg. 72(6), 786-791 (2005). (Pubitemid 41278800)
37. Kongsin S, Jiamton S, Suaya JA et al. Cost of dengue in Thailand. Dengue Bulletin 34, 77-89 (2010).
38. Khun S, Manderson L. Poverty, user fees and ability to pay for health care for children with suspected dengue in rural Cambodia. Int. J. Equity. Health 7, 10-17 (2008).
39. Van Damme W, Van Leemput L, Por I, Hardeman W, Meessen B. Out-of-pocket health expenditure and debt in poor households: evidence from Cambodia. Trop. Med. Int. Health 9(2), 273-280 (2004). (Pubitemid 38250816)
40. Huy R, Wichmann O, Beatty M et al. Cost of dengue and other febrile illnesses to households in rural Cambodia: a prospective community-based case-control study. BMC Public Health 9, 155-162 (2009).
41. Lum LC, Suaya JA, Tan LH, Sah BK, Shepard DS. Quality of life of dengue patients. Am. J. Trop. Med. Hyg. 78(6), 862-867 (2008). (Pubitemid 351967800)
42. Rezza G. Aedes albopictus and the reemergence of Dengue. BMC Public Health 12, 72 (2012).
43. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol. 29, 587-619 (2011).
44. Solomon T, Mallewa M. Dengue and other emerging flaviviruses. J. Infect. 42(2), 104-115 (2001). (Pubitemid 32633350)
45. Chen R, Vasilakis N. Dengue-quo tu et quo vadis? Viruses 3(9), 1562-1608 (2011).
46. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 239(4839), 476-481 (1988). (Pubitemid 18084309)
47. Wu SJ, Grouard-Vogel G, Sun W et al. Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 6(7), 816-820 (2000). (Pubitemid 30469433)
48. Miller JL, de Wet BJ, Martinez-Pomares L et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 4(2), e17 (2008).
49. Hidari KI, Suzuki T. Dengue virus receptor. Trop. Med. Health 39(Suppl. 4), 37-43 (2011).
50. Meertens L, Carnec X, Lecoin MP et al. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12(4), 544-557 (2012).
51. Halstead SB, O'Rourke EJ. Antibodyenhanced dengue virus infection in primate leukocytes. Nature 265(5596), 739-741 (1977). (Pubitemid 8039460)
52. Laoprasopwattana K, Libraty DH, Endy TP et al. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J. Infect. Dis. 192(3), 510-519 (2005). (Pubitemid 41023132)
53. Libraty DH, Acosta LP, Tallo V et al. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6(10), e1000171 (2009).
54. Whitehorn J, Farrar J. Dengue. Br. Med. Bull. 95, 161-173 (2010).
55. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11(8), 532-543 (2011).
56. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 29(42), 7221-7228 (2011).
57. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11(3), 480-496 (1998). (Pubitemid 28379096)
58. Brasier AR, Ju H, Garcia J et al. A three-component biomarker panel for prediction of dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 86(2), 341-348 (2012).
59. Kumar Y, Liang C, Bo Z et al. Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. PLoS Negl. Trop. Dis. 6(11), e1887 (2012).
60. Rathakrishnan A, Wang SM, Hu Y et al. Cytokine expression profile of dengue patients at different phases of illness. PLoS One 7(12), e52215 (2012).
61. Khor CC, Chau TN, Pang J et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat. Genet. 43(11), 1139-1141 (2011).
62. Guzman MG, Kouri G. Dengue: an update. Lancet Infect. Dis. 2(1), 33-42 (2002). (Pubitemid 36109304)
63. Halstead SB. Controversies in dengue pathogenesis. Paediatr. Int. Child Health 32(Suppl. 1), 5-9 (2012).
64. Hadinegoro SR. The revised WHO dengue case classification: does the system need to be modified? Paediatr. Int. Child Health 32(Suppl. 1), 33-38 (2012).
65. Rahman M, Rahman K, Siddque AK et al. First outbreak of dengue hemorrhagic fever, Bangladesh. Emerg. Infect. Dis. 8(7), 738-740 (2002). (Pubitemid 34764745)
66. Rigau-Perez JG. Severe dengue: the need for new case definitions. Lancet Infect. Dis. 6(5), 297-302 (2006).
67. Phuong CX, Nhan NT, Kneen R et al. Clinical diagnosis and assessment of severity of confirmed dengue infections in Vietnamese children: is the World Health Organization classification system helpful? Am. J. Trop. Med. Hyg. 70(2), 172-179 (2004). (Pubitemid 38200522)
68. Balmaseda A, Hammond SN, Pérez MA et al. Short report: assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am. J. Trop. Med. Hyg. 73(6), 1059-1062 (2005). (Pubitemid 43038254)
69. Alexander N, Balmaseda A, Coelho IC et al. Multicentre prospective study on dengue classification in four South-east Asian and three Latin American countries. Trop. Med. Int. Health 16(8), 936-948 (2011).
70. Narvaez F, Gutierrez G, Perez MA et al. Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS Negl. Trop. Dis. 5(11), e1397 (2011).
71. Basuki PS, Budiyanto, Puspitasari D et al. Application of revised dengue classification criteria as a severity marker of dengue viral infection in Indonesia. Southeast Asian J. Trop. Med. Public Health 41(5), 1088-1094 (2010).
72. Barniol J, Gaczkowski R, Barbato EV et al. Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC Infect. Dis. 11, 106 (2011).
73. Peeling RW, Artsob H, Pelegrino JL et al. Evaluation of diagnostic tests: dengue. Nat. Rev. Microbiol. 8(Suppl. 12), S30-38 (2010).
74. De Paula SO, Fonseca BA. Dengue: a review of the laboratory tests a clinician must know to achieve a correct diagnosis. Braz. J. Infect. Dis. 8(6), 390-398 (2004).
75. Buchy P, Yoksan S, Peeling R, Hunsperger E. Working Paper 4.4: Laboratory tests for the diagnosis of dengue virus infection. In: Report of the Scientific Working Group on Dengue. Special Programme for Research and Training in Tropical Diseases UNICEF/UNDP/World Bank and WHO (2007).
76. Kulkarni RD, Patil SS, Ajantha GS et al. Association of platelet count and serological markers of dengue infection-importance of NS1 antigen. Indian J. Med. Microbiol. 29(4), 359-362 (2011).
77. Sathish N, Vijayakumar TS, Abraham P, Sridharan G. Dengue fever: Its laboratory diagnosis, with special emphasis on IgM detection. Dengue Bulletin 27, 116-125 (2003). (Pubitemid 38854670)
78. Balmaseda A, Guzman MG, Hammond S et al. Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. Clin. Diagn. Lab. Immunol. 10(2), 317-322 (2003). (Pubitemid 36314459)
79. de la Cruz Hernandez SI, Gonzalez Mateos S, Flores Aguilar H et al. Evaluation of a novel commercial rapid test for dengue diagnosis based on specific IgA detection. Diagn. Microbiol. Infect. Dis. 72(2), 150-155 (2012).
80. Torresi J. PLoS Negl. Trop. Dis. (2013) (in press).
81. Vanlerberghe V, Toledo ME, Rodriguez M et al. Community involvement in dengue vector control: cluster randomised trial. BMJ. 338, b1959 (2009).
82. Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg. Infect. Dis. 12(6), 887-893 (2006). (Pubitemid 43848408)
83. Luz PM, Vanni T, Medlock J, Paltiel AD, Galvani AP. Dengue vector control strategies in an urban setting: an economic modelling assessment. Lancet 377(9778), 1673-1680 (2011).
84. Rodriguez MM, Bisset JA, Fernandez D. Levels of insecticide resistance and resistance mechanisms in Aedes aegypti from some Latin American countries. J. Am. Mosq. Control. Assoc. 23(4), 420-429 (2007). (Pubitemid 351700511)
85. Nam VS, Yen NT, Holynska M, Reid JW, Kay BH. National progress in dengue vector control in Vietnam: survey for Mesocyclops (Copepoda), Micronecta (Corixidae), and fish as biological control agents. Am. J. Trop. Med. Hyg. 62(1), 5-10 (2000). (Pubitemid 30180344)
86. Kay BH, Tuyet Hanh TT, Le NH et al. Sustainability and cost of a communitybased strategy against Aedes aegypti in northern and central Vietnam. Am. J. Trop. Med. Hyg. 82(5), 822-830 (2010).
87. Walker T, Johnson PH, Moreira LA et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature 476(7361), 450-453 (2011).
88. Turelli M, Hoffmann AA. Rapid spread of an inherited incompatibility factor in California Drosophila. Nature 353(6343), 440-442 (1991). (Pubitemid 21912532)
89. Hoffmann AA, Montgomery BL, Popovici J et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 476(7361), 454-457 (2011).
90. Fu G, Lees RS, Nimmo D et al. Female-specific flightless phenotype for mosquito control. Proc. Natl. Acad. Sci. USA 107(10), 4550-4554 (2010).
91. Wise de Valdez MR, Nimmo D, Betz J et al. Genetic elimination of dengue vector mosquitoes. Proc. Natl. Acad. Sci. USA 108(12), 4772-4775 (2011).
92. Ostera GR, Gostin LO. Biosafety concerns involving genetically modified mosquitoes to combat malaria and dengue in developing countries. JAMA 305(9), 930-931 (2011).
93. Guirakhoo F, Pugachev K, Zhang Z et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78(9), 4761-4775 (2004). (Pubitemid 38501097)
94. Guirakhoo F, Weltzin R, Chambers TJ et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74(12), 5477-5485 (2000). (Pubitemid 30346579)
95. Mantel N, Girerd Y, Geny C et al. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 29(38), 6629-6635 (2011).
96. Guy B, Barban V, Mantel N et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80(2), 302-311 (2009).
97. Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2(2), 60-67 (2006). (Pubitemid 43927159)
98. Morrison D, Legg TJ, Billings CW et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201(3), 370-377 (2010).
99. Guy B, Nougarede N, Begue S et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26(45), 5712-5721 (2008).
100. Poo J, Galan F, Forrat R et al. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naive Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity. Pediatr. Infect. Dis. J. (2010) (Epub ahead of print).
101. Capeding RZ, Luna IA, Bomasang E et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled Phase I trial in the Philippines. Vaccine 29(22), 3863-3872 (2011).
102. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am. J. Trop. Med. Hyg. 85(4), 724-731 (2011).
103. Guy B, Barrere B, Malinowski C et al.From research to Phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29(42), 7229-7241 (2011).
104. Guy B, Chanthavanich P, Gimenez S et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22(27-28), 3563-3574 (2004). (Pubitemid 39099632)
105. Chanthavanich P, Luxemburger C, Sirivichayakul C et al. Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am. J. Trop. Med. Hyg. 75(1), 26-28 (2006). (Pubitemid 351627565)
106. Sabchareon A, Wallace D, Sirivichayakul C et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled Phase 2b trial. Lancet 380(9853), 1559-1567 (2012).
107. Whitehead SS, Falgout B, Hanley KA et al. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77(2), 1653-1657 (2003). (Pubitemid 36055591)
108. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3́ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70(6), 3930-3937 (1996).
109. Blaney JE Jr, Hanson CT, Firestone CY et al. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am. J. Trop. Med. Hyg. 71(6), 811-821 (2004). (Pubitemid 40075635)
110. Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect. Dis. 4, 39 (2004).
111. Whitehead SS, Hanley KA, Blaney JE Jr, et al. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21(27-30), 4307-4316 (2003). (Pubitemid 37138698)
112. Blaney JE Jr, Sathe NS, Goddard L et al. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4. Vaccine 26(6), 817-828 (2008).
113. Durbin AP, McArthur J, Marron JA et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin 2(4), 167-173 (2006). (Pubitemid 44422483)
114. Durbin AP, Whitehead SS, McArthur J et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191(5), 710-718 (2005). (Pubitemid 40271058)
115. Durbin AP, Karron RA, Sun W et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3́-untranslated region. Am. J. Trop. Med. Hyg. 65(5), 405-413 (2001). (Pubitemid 33134570)
116. Durbin AP, McArthur JH, Marron JA et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin. 2(6), 255-260 (2006). (Pubitemid 46025657)
117. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29(42), 7242-7250 (2011).
118. Durbin AP, Kirkpatrick BD, Pierce KK et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double blind clinical trial. J. Infect. Dis. 207(6), 957-965 (2013).
119. Butrapet S, Huang CY, Pierro DJ et al. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5́ noncoding region and nonstructural proteins 1 and 3. J. Virol. 74(7), 3011-3019 (2000). (Pubitemid 30143723)
120. Kinney RM, Butrapet S, Chang GJ et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230(2), 300-308 (1997). (Pubitemid 27211861)
121. Angsubhakorn S, Moe JB, Marchette NJ et al. Neurovirulence effects of dengue-2 viruses on the rhesus (Macaca mulatta) brain and spinal cord. Southeast Asian J. Trop. Med. Public Health 18(1), 52-55 (1987).
122. Huang CY, Butrapet S, Tsuchiya KR et al. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77(21), 11436-11447 (2003). (Pubitemid 37271642)
123. Brewoo JN, Kinney RM, Powell TD et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 30(8), 1513-1520 (2012).
124. Osorio JE, Brewoo JN, Silengo SJ et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques. Am. J. Trop. Med. Hyg. 84(6), 978-987 (2011).
125. Osorio JE, Huang CYH, Kinney RM, Stinchcomb DT. Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29(42), 7251-7260 (2011).
126. Clements DE, Coller BA, Lieberman MM et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28(15), 2705-2715 (2010).
127. Robert Putnak J, Coller BA, Voss G et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23(35), 4442-4452 (2005). (Pubitemid 40991230)
128. Coller B-AG, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29(42), 7267-7275 (2011).
129. Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine 29(42), 7261-7266 (2011).
130. Raviprakash K, Porter KR, Kochel TJ et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J. Gen. Virol. 81(Pt 7), 1659-1667 (2000). (Pubitemid 30427070)
131. Beckett CG, Tjaden J, Burgess T et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 29(5), 960-968 (2011).
132. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect. Dis. 9(11), 678-687 (2009).
133. Letson GW, Singhasivanon P, Fernandez E et al. Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas. Hum. Vaccin. 6(10), 30-37 (2010).
134. Thomas SJ. The necessity and quandaries of dengue vaccine development. J. Infect. Dis. 203(3), 299-303 (2011).
135. Guy B, Almond J, Lang J. Dengue vaccine prospects: a step forward. Lancet 377(9763), 381-382 (2011).
136. Yauch LE, Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res. 80(2), 87-93 (2008).
137. Edelman R. Unique challenges faced by the clinical evaluation of dengue vaccines. Expert Rev. Vaccines 10(2), 133-136 (2011).
138. Lam SK, Burke D, Capeding MR et al. Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine 29(51), 9417-9422 (2011).
139. de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev. Vaccines 7(3), 345-353 (2008). (Pubitemid 351520022)
140. Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum. Vaccin. 6(9), 745-753 (2010).
141. Amarasinghe A, Mahoney RT. Estimating potential demand and supply of dengue vaccine in Brazil. Hum. Vaccin. 7(7), 776-780 (2011).
142. Lam SK, Burke D, Gubler D, Mendez-Galvan J, Thomas L. Call for a World Dengue Day. Lancet 379(9814), 411-412 (2012).